Pembrolizumab has been approved by the FDA for high-risk early-stage triple-negative breast cancer

Share This Post

August 2021: Pembrolizumab (Keytruda, Merck) was approved by the FDA for high-risk, early-stage triple-negative breast cancer (TNBC) as a neoadjuvant treatment in combination with chemotherapy, and later as a single agent as adjuvant treatment following surgery.

Pembrolizumab in conjunction with chemotherapy was also given regular approval by the FDA for patients with locally recurrent unresectable or metastatic TNBC whose tumours express PD-L1 (Combined Positive Score [CPS] 10) as assessed by an FDA-approved test. In November 2020, the FDA gave pembrolizumab expedited approval for this indication.

The neoadjuvant and adjuvant approvals, as well as the confirmatory trial for the accelerated approval, were based on the following trial.

In KEYNOTE-522 (NCT03036488), a randomised, multicenter, double-blind, placebo-controlled trial involving 1174 patients with newly diagnosed previously untreated high-risk early-stage TNBC (tumour size >1 cm but 2 cm) and continued adjuvant treatment with pembrolizumab as a single agent, the efficacy of pembrolizumab in combination with neoadjuvant chemotherapy followed by surgery and continued Patients were included regardless of PD-L1 expression in their tumours.

Pembrolizumab in conjunction with chemotherapy or placebo in combination with chemotherapy were given to patients in a 2:1 ratio. The chemotherapy protocol is detailed in the drug label, which is linked below.

The pathological complete response (pCR) rate and event-free survival were the primary efficacy outcome metrics (EFS). Patients who received pembrolizumab in conjunction with chemotherapy had a pCR rate of 63 percent (95 percent CI: 59.5, 66.4), compared to 56 percent (95 percent CI: 50.6, 60.6) for patients who got chemotherapy alone. The proportion of patients who had an EFS episode was 123 (16%) and 93 (24%), respectively (HR 0.63; 95 percent CI: 0.48, 0.82; p=0.00031).

Fatigue/asthenia, nausea, constipation, diarrhoea, decreased appetite, rash, vomiting, cough, dyspnea, pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, stomatitis, headache, weight loss, abdominal pain, arthralgia, myalgia, and insomnia were the most common adverse reactions reported in approximately 20% of patients in trials of pembrolizumab in combination with chemotherapy.

Pembrolizumab is given as an intravenous infusion over 30 minutes at a dose of 200 mg every three weeks or 400 mg every six weeks for TNBC. For neoadjuvant treatment, pembrolizumab is given in combination with chemotherapy for 24 weeks, and then as a single agent for adjuvant treatment for up to 27 weeks.



Check details here.

Take second opinion on breast cancer treatment

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form